

### Appendix A: Clean Pending Claims

1. A composition for inhibiting vascular endothelial growth factor expression in a cell comprising:

an antisense oligonucleotide directed against vascular endothelial growth factor (VEGF) wherein said antisense oligonucleotide inhibits proliferation of cultured Kaposi's Sarcoma cells at an  $IC_{50}$  concentration of less than or equal to about 1.5 micromolar.

2. The composition of claim 1 wherein said antisense oligonucleotide is selected from the group consisting of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 28 and 29.

3. The composition of Claim 2 wherein said antisense oligonucleotide is encapsulated in a liposome.

4. The composition of Claim 2 further comprising an antibody that specifically interacts with a vascular endothelial growth factor or a vascular endothelial growth factor receptor.

5. The composition of Claim 4 wherein said antibody is specific for Flt-1.

6. The composition of Claim 4 wherein said antibody is specific for Flk-1.

7. The composition of Claim 2 further comprising a second antisense oligonucleotide chosen from the group consisting of SEQ ID NOS: 1-29.

8. The composition of Claim 7 wherein said first and second oligonucleotides are encapsulated in a liposome.

9. The composition of Claim 1 wherein said antisense oligonucleotide inhibits proliferation of cultured ovarian carcinoma cells at an  $IC_{50}$  concentration of less than or equal to about 2 micromolar.

10. The composition of Claim 9 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 9, 10, 13, 14, 17, 28 and 29.

11. The composition of Claim 1 wherein said antisense oligonucleotide inhibits proliferation of cultured melanoma cells at an  $IC_{50}$  concentration of less than or equal to about one micromolar.

12. The composition of Claim 11 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 12, 13, 14, and 17.

13. The composition of Claim 1 wherein said cells are epithelial cells.

14. The composition of Claim 1 wherein said cells are ovarian cancer cells, melanoma cells, Kaposi's sarcoma cells or pancreatic cancer cells.

15. The composition of Claim 14 wherein said cells are metastatic.